Byrl Bioceuticals India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.15 M
as on 16-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1142.72%
(FY 2023)
- Profit -356.86%
(FY 2023)
- Ebitda -530.59%
(FY 2023)
- Net Worth -9440.27%
(FY 2023)
- Total Assets 2.26%
(FY 2023)
About Byrl Bioceuticals India
The Corporate was formerly known as Neuhope Bioceuticals Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Akanksha Jain, Priyata Goyal, and Ankur Goyal serve as directors at the Company.
- CIN/LLPIN
U15400DL2020PTC367927
- Company No.
367927
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Aug 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Byrl Bioceuticals India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akanksha Jain  | Additional Director | 02-Jun-2021 | Current |
| Priyata Goyal | Director | 13-Aug-2020 | Current |
| Ankur Goyal | Additional Director | 15-Jun-2022 | Current |
Financial Performance and Corporate Structure Insights of Byrl Bioceuticals India.
Byrl Bioceuticals India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1142.72% increase. The company also saw a substantial fall in profitability, with a 356.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 9440.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Byrl Bioceuticals India?
Unlock access to Byrl Bioceuticals India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Byrl Bioceuticals India?
Byrl Bioceuticals India has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Byrl Bioceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Byrl Bioceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
